Skip to main content

Table 3 Ongoing long-term prophylaxis medications for HAE reported in patients enrolled in IOS

From: Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

Medication, n (%) Spain
n = 73
Other countries
N = 385
Danazol 29 (39.7) 215 (55.8)
Stanozolol 32 (43.8) 19 (4.9)
Plasma-derived C1 inhibitora 21 (28.8) 87 (22.6)
Tranexamic acid 19 (26.0) 102 (26.5)
Oxandrolone 0 8 (2.1)
Recombinant C1 inhibitor 0 5 (1.3)
Other 5 (6.8) 47 (12.2)
  1. All long-term prophylaxis medications reported at any time during follow-up in IOS are included in the summary; patients may be included in more than one category
  2. HAE hereditary angioedema, IOS Icatibant Outcome Survey
  3. aIncludes Berinert®, Cinryze®, and unspecified C1 inhibitors